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COVID-19 is a pandemic that currently occurs in almost all parts of the world, caused by a new
coronavirus species that can infect humans, namely SARS-CoV-2. To date, there is no effective
drug to treat COVID-19. There are studies proving that the secondary metabolites of pentacyclic
triterpenes have antiviral activity, one of which is asiatic acid. The aims of this study are to obtain
the affinity and interactions of asiatic acid derivative structures in inhibiting the main protease
of SARS-CoV-2. The research method was molecular docking of asiatic acid and its derivatives
against the main protease of SARS-CoV-2 (6LU7) consisting of ligand and receptor preparation,
identification of active site, and molecular docking simulation. The results of this study indicate
that asiatic acid derivative AA9 has the best affinity in inhibiting the main protease of SARSCoV-2 with binding free energy value (∆G) of -9.90 kcal/mol, compared with favipiravir which
has ∆G value of -4.58 kcal/mol. AA9 also has an interaction with the main protease of SARSCoV-2 through hydrogen bonds with Gly143. This present study showed that asiatic acid and its
derivatives have a higher binding affinities to SARS-CoV-2 main protease compared to favipiravir.
Keywords: COVID-19; SARS-CoV-2; asiatic acid; molecular docking

INTRODUCTION
COVID-19 was first reported by a number of patients
with pneumonia with unknown causes that were
epidemiologically related to the animal and seafood
market. A new coronavirus was detected in the epithelial
cells of the respiratory tract patients, named 2019-nCoV
(Zhu et al., 2020) which was later on 11 February 2020
officially changed to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2 by the International
Committee on Taxonomy of Viruses (WHO, 2020).
SARS-CoV-2 is a virus that can cause pneumonia with
clinical presentation closely resembles the infection
caused by SARS-CoV (Huang et al., 2020). The infection
caused by SARS-CoV-2 can cause hyperinflammatory
syndrome that occurs due to a cytokine storm from an
excessive body response to the existence of SARSCoV-2 (Ozdemir, 2020).
One of the potential drug targets in the treatment of
COVID-19 is the main protease (Mpro) of SARS-CoV-2
(PDB code 6LU7). Mpro is a key enzyme in SARS-CoV-2
which plays an important role in the replication and
transcription of the virus, which makes it a promising
drug target for this virus, if the Mpro is inhibited it will
interfere with the course of the virus replication in the
body (Jin et al., 2020).
Utilization of medicinal plants and secondary metabolites

of plants can be an alternative (Yang et al., 2018).
Based on the research of Zhao et al. (2014), pentacyclic
triterpenes are a group of promising secondary plant
metabolites showing antiviral activity. In that research,
asiatic acid became one of the pentacyclic triterpenes
compounds which was tested and demonstrated the
inhibitory activity of virus replication. In addition,
according to Wzoniak et al. (2015) ursolic acid, a
compound of pentacyclic triterpene of the ursane, has a
structure that mimics asiatic acid and showed inhibitory
activity on the protease of human immunodeficiency
virus (HIV).
Asiatic acid is a natural pentacyclic triterpene that
is found in plants, one of which is contained in the
Centella asiatica L (Hashim et al., 2011). Asiatic acid
has a triterpenoid scaffold with hydroxyl groups at the
positions of C2, C3, and C23, as well as the carboxylic
group at the C28 position (Li et al., 2014). Modifications
of the hydroxy and carboxylic groups and rearrangement
of double bonds of asiatic acid result in higher binding
affinity than asiatic acid binding to iNOS enzyme which
has role in synthesizing Nitric Oxide (NO), one of the
mediators of inflammation (Musfiroh et al., 2014).
The current antiviral management for COVID-19 in
Indonesia are oseltamivir and favipiravir (Burhan et
al., 2020). However, oseltamivir has antiviral activity
by inhibiting neuraminidase which prevents the virus
infecting the host cells (Kamali & Holodniy, 2013),
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Table 1. Modification of the structure of asiatic acid (Musfiroh et al., 2014)
Compounds
AA1
AA2
AA3
AA4
AA5
AA6
AA7
AA8
AA9
AA10
AA11
AA12
AA13

C2
OH
OH
OAc
OAc
OAc
Oxo
Oxo
Oxo
Oxo
Oxo
Oxo
Oxo
Oxo

C3
OH
OH
OAc
OAc
OAc
Oxo
Oxo
Oxo
Oxo
Oxo
OH
Oxo
OH

Functional Groups Modification
C23
C11
C13
CH2OH
H
H
CH2OH
H
H
CH2OAc
H
H
CH2OAc
H
H
CH2OAc
Ene
Ene
COOH
Ene
Ene
COOH
Ene
Ene
COOH
H
H
COOCH3
Ene
Ene
COOCH3
Ene
H
CH2OH
H
H
CH3COOH
H
H
CH2OH
H
H

while SARS-CoV-2 does not have neuraminidase. In this
study, affinity predictions were thus performed on asiatic
acid as well as its derivatives and favipiravir against
SARS-CoV-2 Mpro.
METHODS
Preparation of SARS-CoV-2 Mpro and Asiatic Acid
Derivatives Structures
The crystal structure of SARS-CoV-2 Mpro (PDB code
6LU7) was obtained from Protein Data Bank (PDB) and
the native ligand and water molecules were removed
for molecular docking. Favipiravir and asiatic acid
structures were downloaded from PubChem database and
asiatic acid derivatives were designed using ChemDraw
Ultra. The derivative structures of asiatic acid refer to
previous work by Musfiroh et al, 2014 (AA1-AA13), in
which the modification of structure occurs at C-2, C3,
C23, C11, C13 and C23 with methylation, acetylation,
rearrangement of double bond, oxidation of hydroxyl

Figure 1. Asiatic acid structure
E-ISSN 2477-0612
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group and combination of them (Figure 1 and Table 1).
The ligands were optimized with MM2 using Chem3D
pro and converted into the PDB format. For further
analysis, SARS-CoV-2 Mpro and ligands were optimized
and converted into PDBQT format using AutoDockTools.
Active Site Identification
The amino acid residues in the active site of SARSCoV-2 Mpro were identified using Discovery Studio.
Validation of Molecular Docking Method
Validation was performed using AutoDockTools by redocking the native ligand to SARS-CoV-2 Mpro. The
validation was conducted to find out the size and the
coordinate of the grid box that will be used for molecular
docking of test compounds.
Molecular Docking
Molecular docking for all compounds were performed
using AutoDockTools. The grid coordinates were based
on the native ligand position in the binding site of SARSCoV-2 Mpro. The site of affinity map was set to 70 Å x
70 Å x 70 Å with spacing between the grid points set
to 0.375 Å and coordinates of central grid point of
maps were at X = -9.732, Y = 11.403, Z = 68.925. The
molecular docking was performed by regulating the
genetic algorithm parameters, using 100 runs of the GA
criteria.
Visualization and Analysis
The results were visualized and analyzed using
Discovery Studio to find out the interactions that occur
between ligand and SARS-CoV-2 Mpro. Hydrogen bonds,
hydrophobic interactions, other bonds that might occur,
and the distances of the bonds were observed.
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Table 2. Amino acid residues in the active site of SARS-CoV-2 Mpro
Types of Bond
Hydrogen

Amino Acid Residues
Phe140

Binding Distance (Å)
3.19

His163

2.37

His164

2.80

Gly143

2.87

Gln189

2.89

Glu166

2.98

Glu166

2.83

Thr190
His41

2.85
4.27

Met49

4.73

Pro168

4.85

Ala191

4.54

Leu167

5.46

Carbon hydrogen

Met165
His172

4.57
3.72

Amide-π

Met165
Leu141

3.69
4.14

Alkyl dan π-Alkyl

be identified. From the visualization of SARS-CoV-2
Mpro, several amino acid residues interact with the native
ligand in the receptor active site (Figure 2). The results of
visualization of interactions between ligand and receptor
are shown in Table 2.

Figure 2. Interactions between the native ligand and
SARS-CoV-2 Mpro
RESULTS AND DISCUSSION
Active site of SARS-CoV-2 Mpro
Analysis of the active site of SARS-CoV-2 Mpro was
performed by visualizing the interactions that occur
between the native ligand and SARS-CoV-2 Mpro.
Visualization was carried out using Discovery Studio to
see the amino acid residues that interact with their native
ligand therefore the active site of SARS-CoV-2 Mpro can

Validation of Molecular Docking Method
Method validation was conducted by re-docking the
native ligand to SARS-CoV-2 Mpro. The native ligand
of SARS-CoV-2 with PDB code 6LU7 is N3. N3 acts
as an inhibitor of SARS-CoV-2 Mpro by occupying the
substrate binding site (Jin, et al., 2020). The validation
results are shown in Table 3. Root mean square deviation
(RMSD) with grid size of 70 Å x 70 Å x 70 Å is in
accordance with the terms of docking method. The
validation results show the RMSD value ≤ 3 Å meaning
that the method used has met the expected criteria (Jain
and Nicholls, 2008). Visualization of interactions using
AutoDockTools showed three hydrogen bonds between
the native ligand and Glu166, Gly143, and His163.
Molecular Docking of Favipiravir against SARSCoV-2 Mpro
The results of docking a drug molecule used as a treatment
for COVID-19 in Indonesia nowadays (favipiravir) with
SARS-Cov-2 Mpro are shown in Table 4. The docking
of favipiravir against SARS-CoV-2 Mpro (Figure 3) has
E-ISSN 2477-0612
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Table 3. Results of re-docking the native ligand to the active site of SARS-CoV-2 Mpro
Compound

∆G
(kcal/mol)

Inhibition
Constant (μM)

RMSD (Å)

N3

-8.30

0.82

2.843

Amino Acid Residues
(Hydrogen Bonds)
Glu166
Gly143
His163

Table 4. Molecular docking results of favipiravir against SARS-CoV-2 Mpro
Compound

Favipiravir

∆G
(kcal/mol)

-4.58

Inhibition
Constant (μM)

441.04

Amino Acid Residues
(Hydrogen Bonds)
Asn142

Binding
Distance (Å)
2.07

Phe140

2.24

Glu166

1.82

His16

2.32

His163

1.83

Ser144

2.79

Cys145

2.37

Cys145

2.84

Discovery Studio, favipiravir tends to have hydrogen
bonds because it has a lot of hydrogen bonds donors
and acceptors, and this is supported by the fact that
favipiravir has hydrogen atoms in primary and secondary
amine groups as hydrogen bond donors and it also has
tertiary amine groups, carbonyl and halogen (in the
form of fluorine) which act as hydrogen bond acceptors.
However, favipiravir has an unfavorable donor-donor
bond with His172 which indicates the repulsion between
two atoms.

Figure 3. Interactions between favipiravir
and SARS-CoV-2 Mpro
shown several hydrogen bonds (green dotted lines)
between favipiravir and Asn142, Phe140, Glu166,
His163, Ser144, and Cys145. When compared with
the native ligand of SARS-CoV-2 Mpro, favipiravir has
similar interactions with Phe140, Glu166, and His163.
Hydrogen bonds between favipiravir and SARS-CoV-2
Mpro occur through the bonding of hydrogen atoms in
the primary amine group with Phe140 and Glu166 with
distances of 2.24 Å and 1.82 Å, respectively and with
His163 through bonds between oxygen and nitrogen
atoms in favipiravir with distances of 1.83 Å and 2.32
Å, respectively. The docking results also showed that the
∆G0 needed for the interaction between favipiravir and
SARS-CoV-2 Mpro was -4.58 kcal/mol and the inhibition
constant was 441.04 µM. Based on an analysis using
E-ISSN 2477-0612

Figure 4. Interactions between AA9 and SARSCoV-2 Mpro
Molecular docking of Asiatic Acid and its Derivatives
to SARS-CoV-2 Mpro
Molecular docking of asiatic acid (Figure 4) and its
derivatives against SARS-CoV-2 Mpro (PDB code 6LU7)
was carried out to predict the affinity of these compounds.
The asiatic acid derivative structures refer to the
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Table 5. Molecular docking results of asiatic acid and its derivatives against SARS-CoV-2 Mpro
Compounds

∆G
(kcal/mol)

Inhibition
Constant (μM)

Amino Acid Residues
(Hydrogen Bonds)

Binding
Distance (Å)

AA1

-7.91

1.59

Thr26

1.84

Cys145

2.28

Glu166

2.49

Gln189

1.96

Gln 189
Cys145

1.88
3.17

Cys145

2.48

Ser144

2.64

Ser46

2.86

1.15

Ser46
Thr26

1.85
1.90

0.91

Cys145
Cys145

2.51
1.93

Asn142

2.95

0.03

His163
Gln192

1.94
2.36

0.56
1.39

Gly143
Gly143
Asn142

2.19
2.19
2.01

Gly143

2.18

0.37

Glu166
Cys145

2.11
2.27

0.05
0.69

Glu166
Gly143
Cys145

1.95
2.24
3.03

Ser144

2.44

Thr45
Asn142
Thr26

2.95
2.24
2.25

Cys145

2.55

Gly143

2.13

Glu166
His41

2.24
2.00

Asn142

1.77

AA2

AA3
AA4

AA5
AA6
AA7

AA8
AA9
AA10

AA11
AA12

AA13

-8.03

-8.10
-8.24

-10.15
-8.52
-7.99

-8.77
-9.90
-8.40

-9.05
-8.54

-8.44

1.30

0.23
0.54

0.65
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Table 6. Number of cluster of asiatic acid and its derivatives
Compounds
AA1
AA4
AA5
AA7
AA8
AA9
AA12

∆G
(kcal/mol)
-7.91
-8.24
-10.15
-7.99
-8.77
-9.90
-8.54

Inhibition
Constant (μM)
1.59
0.91
0.03
1.39
0.37
0.05
0.54

Number of Cluster
25/100
9/100
7/100
55/100
14/100
49/100
32/100

Table 7. Interactions of AA9 with the active site of SARS-CoV-2 Mpro
Types of Bond
Hydrogen
Alkyl dan π-Alkyl

Amino Acid Residues
Gly143
His163
Cys145
Cys145
Cys145
Leu27
Met49
His41
His41
His41

previous study by Musfiroh et al (2014). Modification of
the structure of asiatic acid was carried out in the active
site of hydroxy groups C2, C3, C23, carboxylic group
C28, and rearrangement of double bonds C11 and C13.
Structural modifications were carried out as shown in
Table 1.
Molecular docking results showed that the interactions
between asiatic acid with SARS-CoV-2 Mpro has more
hydrogen bonds compared to all asiatic acid derivatives
as shown in Table 5. Asiatic acid has hydrogen bonds
with Thr26, Cys145, Glu166 and Gln189 and shows
a similarity with the native ligand in terms of the
interactions with Glu166 and Gln189. However, there
are some derivatives of asiatic acid that did not have any
interaction with amino acid residues that interact with the
native ligand, including compounds AA2, AA3, AA10,
AA11, and AA13. This made only compounds AA1,
AA4, AA5, AA7, AA8, AA9 and AA12 as compounds
that have the potential to inhibit SARS-CoV-2 Mpro.
On the other hand, despite having a hydrogen bond
similar with the native ligand in Gly143, AA6 also has
an unfavorable acceptor-acceptor bond which affects
the stability of the compound activity. All unfavorable
protein-ligand interactions will reduce the stability of the
complex because they indicate the repulsion that occurs
between 2 molecules or atoms (Dhorajiwla et al., 2019).
Molecular docking results showed that asiatic acid and
E-ISSN 2477-0612

Binding Distance (Å)
2.24
5.04
3.54
4.32
5.38
4.94
4.69
4.16
4.89
5.26

its derivatives have negative binding free energies,
indicating that the receptor-ligand interaction take place
spontaneously (Du et al., 2016). The results (Table
5) showed that all asiatic acid derivatives have lower
binding free energies compared to asiatic acid which has
∆G value of -7.91 kcal/mol. However, based on binding
free energy, AA5 is the most stable compound when
binding to SARS-CoV-2 Mpro because the lower value of
binding free energy indicates a higher level of stability
when the ligand binds to the receptor, and this can cause
stronger bonds to form. If the results of the molecular
docking of asiatic acid and its derivatives are compared
with favipiravir which has a Ki value of 441.04 µM and
a ∆G value of -4.58 kcal/mol, AA1, AA4, AA5, AA7,
AA8, AA9 and AA12 have better potential in inhibiting
the action of the main protease of SARS-CoV-2.
The selection of the most potential compound to inhibit
SARS-CoV-2 Mpro was conducted further by looking at
another factor, namely a number of clusters, which is
the number of conformations formed when a ligand is
docked to the active site of the receptor. In this study,
each ligand was docked 100 times into the active site
of the receptor, and the more conformations that are
formed each time a ligand was docked, the more stable
the ligand in the conformation. As shown in Table 6,
AA5 has the lowest energy but also very low number of
clusters (7/100), while AA7 has the highest number of
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clusters (55/100), but also a high value of binding free
energy. In contrast, AA9 has higher energy than AA5 but
also has a higher number of clusters (49/100) which is
quite similar to AA7. This indicates that AA9 is much
more stable compared with these compounds.

Du, X., Li, Y., Xia, Y.L., Ai, S.M., Liang, J., Sang, P.,
Ji, X.L., and Liu, S.Q. (2016). Insights into protein–
ligand interactions: mechanisms, models, and methods.
International Journal of Molecular Sciences, 17(2), 144.

The results of docking AA9 to the active site of SARSCoV-2 Mpro can be seen in Figure 4 and Table 7, showing
a hydrogen bond formed by oxygen atoms of AA9 with
Gly143, with the distance of 2.24 Å. This bond occurs
with the involvement of oxygen atom in the ester group
at C28 of AA9. In addition, AA9 also has hydrophobic
interactions between alkyl groups at C29 and C30 with
Met49 and Cys145 and π-alkyl interactions between
aromatic groups, C27, C29, and C30 with Leu27, His41,
and His163.
CONCLUSION
Asiatic acid and its derivatives have shown higher binding
affinities to SARS-CoV-2 main protease compared
to favipiravir. Moreover, the strongest inhibition is
shown by AA9 with ∆G value of -9.90 kcal/mol. AA9
has a structure modification from asiatic acid to oxo
groups at C2 and C3, acetyl at C23, methyl at C28 and
rearrangement of double bonds at C12. The interactions
of AA9 with the active site of SARS-CoV-2 Mpro are
through hydrogen bonds with Gly143 (distance of 2.24
Å), hydrophobic interactions between alkyl groups at
C29 and C30 with Met49 and Cys145, respectively, and
π-alkyl interactions between the aromatic groups, C27,
C29 and C30 in AA9 with Leu27, His41, and His163,
respectively.
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